US 9067989
Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
granted A61KA61K2039/505A61K38/13
Quick answer
US patent 9067989 (Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders) held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
- Grant date
- Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K38/13, A61K38/215, A61P